ArticleCancer cell2015
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.
Abstract read
In one paragraph
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A Case-Control Study.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Trial
- RNA splicing in health and disease.Molecular biomedicine · 2026Review
- STING deficiency does not rescue short telomere-mediated aging phenotypes and longevity in TERC- or TERT-telomerase deficient mice.Cell reports · 2026Article
- Therapeutic inhibition of telomeric DNA damage response rescues hematopoietic dysfunction driven by telomere shortening and aging.Nature aging · 2026Article
- Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.JCO oncology practice · 2026Review
- Diagnosis and management of adult telomere biology disorders.Haematologica · 2026Review
- Telomere Length Abnormality: Investigating Approaches and Correlations with Cancer, Bone Marrow Failure and Hematological Malignancies.Biomedicines · 2025Review
- The role of telomeres in leukemic stem cells function.Regenerative therapy · 2025Review
- Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity.Cell stem cell · 2025Article
- Telomere function and regulation from mouse models to human ageing and disease.Nature reviews. Molecular cell biology · 2025Review
- Hematological complications in solid organ transplant recipients with telomere biology disorders: a narrative review.Frontiers in immunology · 2025Review
- Function of serine/arginine-rich splicing factors in hematopoiesis and hematopoietic malignancies.Cancer cell international · 2024Review
- Tissue mosaicism following stem cell aging: blood as an exemplar.Nature aging · 2024Review
- Senescence Promotes the Recovery of Stemness among Cancer Cells via Reprograming.Biomolecules · 2024Review
- Telomeres: Dysfunction, Maintenance, Aging and Cancer.Aging and disease · 2023Review
- Telomere length and hTERT genetic variants as potential prognostic markers in multiple myeloma.Scientific reports · 2023Article
- Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.Cell reports. Medicine · 2023Review
- The importance of critically short telomere in myelodysplastic syndrome.Biomarker research · 2022Article
- ZetaSuite: computational analysis of two-dimensional high-throughput data from multi-target screens and single-cell transcriptomics.Genome biology · 2022Article
- Clonal hematopoiesis: Mutation-specific adaptation to environmental change.Cell stem cell · 2022Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
42 authors.
Simona CollaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: scolla@mdanderson.org.
Derrick Sek Tong OngDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yamini OgotiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Matteo MarchesiniDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nipun A MistryDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Karen Clise-DwyerDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sonny A AngDepartment of Pediatric Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Paola StortiDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Hematology, Department of Clinical and Experimental Medicine, University of Parma, 43126 Parma, Italy.
Andrea VialeDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nicola GiulianiHematology, Department of Clinical and Experimental Medicine, University of Parma, 43126 Parma, Italy.
Kathryn RuisaardDepartment of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Irene Ganan GomezDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Christopher A BristowInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marcos EstecioDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
David C WeksbergDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yan Wing HoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Baoli HuDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Giannicola GenoveseDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Piergiorgio PettazzoniDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Asha S MultaniDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shan JiangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sujun HuaDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael C RyanIn Silico Solutions, Falls Church, VA 22043, USA.
Alessandro CarugoDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Luigi NeziDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yue WeiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hui YangDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Marianna D'AncaDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Li ZhangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sarah GaddisDepartment of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
Ting GongDepartment of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.
James W HornerInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Timothy P HeffernanInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Philip JonesInstitute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Laurence J N CooperDepartment of Pediatric Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Han LiangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Y Alan WangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lynda ChinDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carlos Bueso-RamosDepartment of Hematopathology, University of Texas MD Cancer Center, Houston, TX 77030, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ronald A DePinhoDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rdepinho@mdanderson.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MIntegrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)U24CA143883 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, MILLS, GORDON B. · 2009 to 2016
$10.6MTELOMERASE IN DEVELOPMENT, SENESCENCE AND NEOPLASIAR01CA084628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2000 to 2019
$10.5MNCI NIH HHS CA143883NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA16672NCI NIH HHS R01 CA084628NCI NIH HHS U24 CA143883
Abstract
Myelodysplastic syndrome (MDS) risk correlates with advancing age, therapy-induced DNA damage, and/or shorter telomeres, but whether telomere erosion directly induces MDS is unknown. Here, we provide the genetic evidence that telomere dysfunction-induced DNA damage drives classical MDS phenotypes and alters common myeloid progenitor (CMP) differentiation by repressing the expression of mRNA splicing/processing genes, including SRSF2. RNA-seq analyses of telomere dysfunctional CMP identified aberrantly spliced transcripts linked to pathways relevant to MDS pathogenesis such as genome stability, DNA repair, chromatin remodeling, and histone modification, which are also enriched in mouse CMP haploinsufficient for SRSF2 and in CD34(+) CMML patient cells harboring SRSF2 mutation. Together, our studies establish an intimate link across telomere biology, aberrant RNA splicing, and myeloid progenitor differentiation.
Indexed as
TelomereAnimalsCell DifferentiationHaploinsufficiencyHematopoiesisHumansMiceMyelodysplastic SyndromesNuclear ProteinsRibonucleoproteinsRNA SplicingSerine-Arginine Splicing FactorsNuclear ProteinsRibonucleoproteinsSerine-Arginine Splicing FactorsSRSF2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.